查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830847

2025年全球非病毒基因遞送技術市場報告

Non-Viral Gene Delivery Technologies Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，非病毒基因轉殖技術市場發展迅速，預計從2024年的39.6億美元成長到2025年的45.7億美元，複合年成長率達15.6%。預測期內的成長歸因於基因研究的擴展、慢性遺傳疾病盛行率的上升、生物技術和製藥研發活動的增加、遺傳和分子生物學研究的進步以及政府和機構資金的增加。

預計未來幾年，非病毒基因遞送市場將快速成長，到2029年市場規模將達到80.6億美元，複合年成長率（CAGR）為15.2%。預測期內的成長可歸因於個性化醫療需求的不斷成長、其在癌症和罕見疾病研究中的日益普及、CRISPR和其他基因編輯技術的進步、基於mRNA的療法的快速發展以及細胞療法和組織工程的持續成長。這段時期的主要趨勢包括脂質奈米顆粒和聚合物載體的開發、基於DNA和RNA的療法的開發及其與人工智慧和計算建模的結合、新一代脂質奈米顆粒（LNP）的出現以及奈米技術的持續進步。

非病毒基因轉移技術是指無需依賴病毒作為載體即可將遺傳物質導入細胞的方法。這些方法能夠實現精準可控的基因遞送，同時降低與病毒系統相關的安全風險和免疫反應。其主要目的是改變或調控基因表現，用於治療遺傳性疾病和推進細胞療法的發展。

非病毒基因轉移技術的主要產品類型包括試劑和套件、遞送裝置以及預拌奈米顆粒。試劑和套件是即用型化學製劑，旨在無需病毒即可將遺傳物質遞送至細胞內。遞送方式多種多樣，包括體外、體內和離體，可採用的技術包括電穿孔、脂質體轉染、聚合物轉染、物理方法（例如顯微注射和基因槍）以及奈米顆粒。這些技術可應用於基因治療、DNA疫苗、 RNA干擾（RNAi）、CRISPR/Cas9基因編輯和蛋白質表現等領域。最終用戶包括生物技術和生物製藥公司、研究機構和學術機構。

美國在2025年春季突然提高關稅及其引發的貿易摩擦對製藥公司造成了嚴重衝擊。利潤豐厚的學名藥生產商尤其脆弱，一些公司不得不縮減低收益藥物的生產規模。生物技術公司也因關稅導致的專用試劑短缺而面臨臨床試驗延期。為因應這一局面，製藥業正在印度和歐洲擴大原料藥的生產，增加庫存，並遊說政府對基本藥物給予貿易豁免。

《非病毒基因轉移技術市場研究報告》是商業研究公司最新發布的系列報告之一，提供非病毒基因轉移技術市場統計數據，例如全球市場規模、區域佔有率、競爭對手及其市場佔有率、詳細的市場細分、市場趨勢和商業機會，為您提供在非病毒基因轉移技術行業取得成功所需的數據。本報告透過對產業現狀和未來發展趨勢的詳細分析，為您提供所需的一切資訊。

未來幾年，對個人化醫療日益成長的需求預計將推動非病毒基因轉移技術市場的成長。個人化醫療是一種醫療保健方法，它根據個人獨特的基因組成、生活方式和環境因素，量身定做預防、診斷和治療方案。基因組定序技術的進步推動了這項需求的成長，該技術能夠實現更精準的診斷、標靶治療，並為每位患者提供更完善、更個人化的治療效果。非病毒基因轉移技術在這一趨勢中發揮關鍵作用，因為它提供了一種更安全、更靈活的方式，可以根據患者的基因譜遞送治療基因，而無需承擔病毒載體相關的安全風險。例如，美國非營利組織個人化醫療聯盟（Personalized Medicine Coalition）於2024年2月報告稱，美國食品藥物管理局（FDA）在2023年核准了16種用於治療罕見疾病患者的新型個人化療法（2022年批准了6種）。因此，個人化醫療的日益普及正在推動對非病毒基因轉移技術的需求。

非病毒基因遞送市場的公司也積極探索非病毒基因治療平台等創新技術，以提高基因治療的安全性和精準性。這些平台無需病毒即可將治療性基因或核酸遞送至細胞內，從而實現針對多種疾病的精準可控基因治療，同時降低免疫反應和其他安全隱患的風險。例如，2023年10月，美國生物技術公司Generation Bio宣布推出免疫靜止DNA（iqDNA），它是封閉式末端DNA（ceDNA）的改良版本。這種新型DNA能夠逃避免疫系統的檢測，並且在小鼠和非人靈長類動物中，透過脂質奈米顆粒（LNP）系統給藥後，其細胞激素水平和耐受性與化學修飾的mRNA相當。由於其安全性更高，Generation Bio正優先將iqDNA作為其研發項目（包括其領先的A型血友病治療項目）的主要DNA載體。

2023年9月，美國製藥公司SOHM Inc.收購了ABBIE Inc.，具體金額未揭露。 SOHM Inc.是一家專注於學名藥和自有品牌藥物的製藥公司。此次收購鞏固了SOHM在非病毒基因轉移技術領域的地位，增強了其開發下一代基因編輯解決方案的能力，並擴大了其在基因治療市場的佔有率。 ABBIE Inc.是一家總部位於美國的基因編輯平台公司，致力於開發用於基因有效載荷的非病毒載體遞送系統。

非病毒基因轉移技術市場由提供服務的營業單位所獲得的收益所構成，這些服務包括配製遺傳物質、開發遞送系統和最佳化轉染。市場價值還包括服務供應商銷售的任何相關商品的價值，或包含在其服務產品中的任何相關商品的價值。非病毒基因轉移技術市場還包括脂質奈米顆粒、聚合物載體、電穿孔裝置和顯微注射系統的銷售。此市場的價值代表“出廠價”，即製造商或生產商銷售商品的價值，無論銷售對像是其他營業單位（包括下游製造商、經銷商和零售商）還是直接銷售給最終客戶。該市場中的商品價值還包括製造商提供的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球非病毒基因轉殖技術：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 終端用戶產業分析
  • 全球非病毒基因遞送技術市場：成長率分析
  • 全球非病毒基因遞送技術市場表現：規模與成長，2019-2024年
  • 全球非病毒基因遞送技術市場預測：規模與成長，2024-2029年，2034年
  • 全球非病毒基因遞送技術：潛在市場規模 (TAM)

第6章 市場細分

  • 全球非病毒基因遞送技術市場：依產品、效能及預測分類，2019-2024年、2024-2029年、2034年
  • 試劑和套件
  • 輸送裝置
  • 預製奈米顆粒
  • 全球非病毒基因遞送技術市場：依遞送方式、效能與預測分類，2019-2024年、2024-2029年、2034年
  • 體外
  • 體內
  • 體外
  • 全球非病毒基因遞送技術市場：依技術、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 電穿孔
  • 基於脂質的轉染
  • 基於聚合物的轉染
  • 物理方法（顯微注射、基因槍）
  • 奈米顆粒
  • 全球非病毒基因傳遞技術市場：按應用、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 基因治療
  • 去氧核糖核酸（DNA）疫苗
  • 核糖核酸干擾（RNAi）
  • 叢集的規律間隔的短回文重複序列（CRISPR）或Cas9基因編輯
  • 蛋白質表現
  • 全球非病毒基因遞送技術市場依最終用途、性能及預測分類，2019-2024年、2024-2029年、2034年
  • 生物技術和生物製藥公司
  • 研究和學術機構
  • 其他用途
  • 全球非病毒基因遞送技術市場：按試劑和套件（按類型）細分、性能和預測，2019-2024年、2024-2029年、2034年
  • 轉染試劑
  • 質體去氧核糖核酸（DNA）套件
  • 信使核糖核酸 (RNA) 遞送試劑套件
  • 小干擾核糖核酸 (RNA) 遞送試劑套件
  • 叢集規律間隔短回文重複序列相關蛋白試劑
  • 細胞特異性遞送試劑
  • 全球非病毒基因遞送技術市場：按遞送裝置（類型）、性能和預測進行細分，2019-2024年、2024-2029年、2034年
  • 電穿孔系統
  • 顯微注射系統
  • 基因槍或生物彈道輸送裝置
  • 超音波介導輸送裝置
  • 動態基因傳遞系統
  • 全球非病毒基因遞送技術市場：按預製奈米顆粒（類型）細分、性能和預測，2019-2024年、2024-2029年、2034年
  • 脂質奈米粒子
  • 聚合物基奈米粒子
  • 金基奈米粒子
  • 基於樹狀聚合物聚合物的奈米粒子
  • 奈米碳管管基奈米顆粒
  • 無機奈米粒子

第7章 區域和國家分析

  • 全球非病毒基因傳遞技術市場：按地區、績效和預測分類，2019-2024年、2024-2029年、2034年
  • 全球非病毒基因遞送技術市場：國家、績效及預測，2019-2024年、2024-2029年、2034年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 非病毒基因遞送技術市場：競爭格局
  • 非病毒基因遞送技術市場：公司概況
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Boehringer Ingelheim GmbH
  • Agilent Technologies Inc.
  • Lonza Group AG
  • Sartorius AG
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corp.
  • Takara Bio Inc.
  • GenScript Biotech Corporation
  • Poseida Therapeutics Inc.
  • ElevateBio LLC
  • ProBio Inc.
  • ReCode Therapeutics Inc.
  • Altogen Biosystems Inc.
  • Generation Bio
  • Indee Labs Inc.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年非病毒基因遞送技術市場：提供新機會的國家
  • 2029年非病毒基因遞送技術市場：充滿新機會的細分市場
  • 2029年非病毒基因遞送技術市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r37838

Non-viral gene delivery technologies are approaches for transferring genetic material into cells without relying on viruses as carriers. These methods reduce safety risks and immune responses associated with viral systems while allowing for precise and controlled delivery. Their primary purpose is to modify or regulate gene expression for the treatment of genetic disorders and the advancement of cell-based therapies.

The main product categories in non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without the use of viruses. Delivery can be achieved through various modes, such as in vitro, in vivo, and ex vivo, using technologies like electroporation, lipid-based transfection, polymer-based transfection, physical methods (e.g., microinjection and gene gun), and nanoparticles. These technologies have applications in gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. End users include biotechnology and biopharmaceutical companies, research and academic institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. The non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.96 billion in 2024 to $4.57 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth during the historic period can be attributed to the expansion of genetic research, the rising prevalence of chronic genetic disorders, increasing biotechnology and pharmaceutical R\&D activities, advancements in genetic and molecular biology research, and greater government and institutional funding.

The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $8.06 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing adoption in cancer and rare disease research, the advancement of CRISPR and other gene editing technologies, rapid expansion of mRNA-based therapeutics, and the continued growth of cell therapy and tissue engineering. Key trends expected during this period include advancements in lipid nanoparticles and polymer-based vectors, the development of DNA- and RNA-based therapeutics, integration with artificial intelligence and computational modeling, the emergence of next-generation lipid nanoparticles (LNPs), and continued progress in nanotechnology.

The rising demand for personalized medicine is expected to drive the growth of the non-viral gene delivery technologies market in the coming years. Personalized medicine is a healthcare approach that tailors prevention, diagnosis, and treatment to an individual's unique genetic makeup, lifestyle, and environmental factors. This growing demand is fueled by advances in genomic sequencing technologies, which enable more precise diagnoses, targeted therapies, and improved treatment outcomes customized to each patient. Non-viral gene delivery technologies play a key role in this trend, as they provide safer and more flexible methods for delivering therapeutic genes based on a patient's genetic profile, without the safety risks associated with viral vectors. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases in 2023, compared with 6 approvals in 2022. Therefore, the growing adoption of personalized medicine is fueling the demand for non-viral gene delivery technologies.

Companies in the non-viral gene delivery market are also advancing innovations such as non-viral genetic medicine platforms to improve the safety and precision of gene therapies. These platforms deliver therapeutic genes or nucleic acids into cells without using viruses, lowering the risk of immune responses and other safety concerns while enabling controlled and accurate gene therapy for various diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company, introduced immune-quiet DNA (iqDNA), an enhanced version of its closed-ended DNA (ceDNA). This novel DNA avoids innate immune system detection and demonstrated cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered through its lipid nanoparticle (LNP) system. Due to its improved safety profile, Generation Bio is prioritizing iqDNA as the main DNA cargo across its programs, including its lead hemophilia A treatment.

In September 2023, SOHM Inc., a US-based pharmaceutical company specializing in generic and private-label drugs, acquired ABBIE Inc. for an undisclosed sum. This acquisition strengthens SOHM's position in non-viral gene delivery technologies, enhancing its capacity to develop next-generation gene-editing solutions and expand its footprint in the genetic therapeutics market. ABBIE Inc. is a US-based gene-editing platform company that develops non-viral vector-based delivery systems for genetic payloads.

Major players in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Gene Delivery Technologies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-viral gene delivery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral gene delivery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral gene delivery technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Reagents And Kits; Delivery Devices; Pre-Formulated Nanoparticles
  • 2) By Delivery: In-Vitro; In-Vivo; Ex-Vivo
  • 3) By Technology: Electroporation; Lipid-Based Transfection; Polymer-Based Transfection; Physical Methods (Microinjection, Gene Gun); Nanoparticles
  • 4) By Application: Gene Therapy; Deoxyribonucleic Acid (DNA) Vaccines; Ribonucleic Acid Interference (RNAi); Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing; Protein Expression
  • 5) By End-Use: Biotechnology And Biopharmaceutical Companies; Research And Academic Institutes; Other End-Uses
  • Subsegments:
  • 1) By Reagents And Kits: Transfection Reagents; Plasmid Deoxyribonucleic Acid (DNA) Kits; Messenger Ribonucleic Acid (RNA) Delivery Kits; Small Interfering Ribonucleic Acid (RNA) Delivery Kits; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents; Cell-Specific Delivery Reagents
  • 2) By Delivery Devices: Electroporation Systems; Microinjection Systems; Gene Guns Or Biolistic Delivery Devices; Ultrasound-Mediated Delivery Devices; Hydrodynamic Gene Delivery Systems
  • 3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles; Polymer-Based Nanoparticles; Gold-Based Nanoparticles; Dendrimer-Based Nanoparticles; Carbon Nanotube-Based Nanoparticles; Inorganic Compound-Based Nanoparticles
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Evonik Industries AG; Moderna Inc.; Boehringer Ingelheim GmbH; Agilent Technologies Inc.; Lonza Group AG; Sartorius AG; Bio-Rad Laboratories Inc.; Bio-Techne Corp.; Takara Bio Inc.; GenScript Biotech Corporation; Poseida Therapeutics Inc.; ElevateBio LLC; ProBio Inc.; ReCode Therapeutics Inc.; Altogen Biosystems Inc.; Generation Bio; Indee Labs Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Viral Gene Delivery Technologies Market Characteristics

3. Non-Viral Gene Delivery Technologies Market Trends And Strategies

4. Non-Viral Gene Delivery Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Non-Viral Gene Delivery Technologies Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Non-Viral Gene Delivery Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Non-Viral Gene Delivery Technologies Market Growth Rate Analysis
  • 5.4. Global Non-Viral Gene Delivery Technologies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Non-Viral Gene Delivery Technologies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Non-Viral Gene Delivery Technologies Total Addressable Market (TAM)

6. Non-Viral Gene Delivery Technologies Market Segmentation

  • 6.1. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents And Kits
  • Delivery Devices
  • Pre-Formulated Nanoparticles
  • 6.2. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • In-Vitro
  • In-Vivo
  • Ex-Vivo
  • 6.3. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Electroporation
  • Lipid-Based Transfection
  • Polymer-Based Transfection
  • Physical Methods (Microinjection, Gene Gun)
  • Nanoparticles
  • 6.4. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gene Therapy
  • Deoxyribonucleic Acid (DNA) Vaccines
  • Ribonucleic Acid Interference (RNAi)
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing
  • Protein Expression
  • 6.5. Global Non-Viral Gene Delivery Technologies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biotechnology And Biopharmaceutical Companies
  • Research And Academic Institutes
  • Other End-Uses
  • 6.6. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transfection Reagents
  • Plasmid Deoxyribonucleic Acid (DNA) Kits
  • Messenger Ribonucleic Acid (RNA) Delivery Kits
  • Small Interfering Ribonucleic Acid (RNA) Delivery Kits
  • Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents
  • Cell-Specific Delivery Reagents
  • 6.7. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Delivery Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Electroporation Systems
  • Microinjection Systems
  • Gene Guns Or Biolistic Delivery Devices
  • Ultrasound-Mediated Delivery Devices
  • Hydrodynamic Gene Delivery Systems
  • 6.8. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Pre-Formulated Nanoparticles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lipid-Based Nanoparticles
  • Polymer-Based Nanoparticles
  • Gold-Based Nanoparticles
  • Dendrimer-Based Nanoparticles
  • Carbon Nanotube-Based Nanoparticles
  • Inorganic Compound-Based Nanoparticles

7. Non-Viral Gene Delivery Technologies Market Regional And Country Analysis

  • 7.1. Global Non-Viral Gene Delivery Technologies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Non-Viral Gene Delivery Technologies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Viral Gene Delivery Technologies Market

  • 8.1. Asia-Pacific Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Viral Gene Delivery Technologies Market

  • 9.1. China Non-Viral Gene Delivery Technologies Market Overview
  • 9.2. China Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Viral Gene Delivery Technologies Market

  • 10.1. India Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Viral Gene Delivery Technologies Market

  • 11.1. Japan Non-Viral Gene Delivery Technologies Market Overview
  • 11.2. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Viral Gene Delivery Technologies Market

  • 12.1. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Viral Gene Delivery Technologies Market

  • 13.1. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Viral Gene Delivery Technologies Market

  • 14.1. South Korea Non-Viral Gene Delivery Technologies Market Overview
  • 14.2. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Viral Gene Delivery Technologies Market

  • 15.1. Western Europe Non-Viral Gene Delivery Technologies Market Overview
  • 15.2. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Viral Gene Delivery Technologies Market

  • 16.1. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Viral Gene Delivery Technologies Market

  • 17.1. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Viral Gene Delivery Technologies Market

  • 18.1. France Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Viral Gene Delivery Technologies Market

  • 19.1. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Viral Gene Delivery Technologies Market

  • 20.1. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Viral Gene Delivery Technologies Market

  • 21.1. Eastern Europe Non-Viral Gene Delivery Technologies Market Overview
  • 21.2. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Viral Gene Delivery Technologies Market

  • 22.1. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Viral Gene Delivery Technologies Market

  • 23.1. North America Non-Viral Gene Delivery Technologies Market Overview
  • 23.2. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Viral Gene Delivery Technologies Market

  • 24.1. USA Non-Viral Gene Delivery Technologies Market Overview
  • 24.2. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Viral Gene Delivery Technologies Market

  • 25.1. Canada Non-Viral Gene Delivery Technologies Market Overview
  • 25.2. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Viral Gene Delivery Technologies Market

  • 26.1. South America Non-Viral Gene Delivery Technologies Market Overview
  • 26.2. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Viral Gene Delivery Technologies Market

  • 27.1. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Viral Gene Delivery Technologies Market

  • 28.1. Middle East Non-Viral Gene Delivery Technologies Market Overview
  • 28.2. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Viral Gene Delivery Technologies Market

  • 29.1. Africa Non-Viral Gene Delivery Technologies Market Overview
  • 29.2. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Company Profiles

  • 30.1. Non-Viral Gene Delivery Technologies Market Competitive Landscape
  • 30.2. Non-Viral Gene Delivery Technologies Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Viral Gene Delivery Technologies Market Other Major And Innovative Companies

  • 31.1. Boehringer Ingelheim GmbH
  • 31.2. Agilent Technologies Inc.
  • 31.3. Lonza Group AG
  • 31.4. Sartorius AG
  • 31.5. Bio-Rad Laboratories Inc.
  • 31.6. Bio-Techne Corp.
  • 31.7. Takara Bio Inc.
  • 31.8. GenScript Biotech Corporation
  • 31.9. Poseida Therapeutics Inc.
  • 31.10. ElevateBio LLC
  • 31.11. ProBio Inc.
  • 31.12. ReCode Therapeutics Inc.
  • 31.13. Altogen Biosystems Inc.
  • 31.14. Generation Bio
  • 31.15. Indee Labs Inc.

32. Global Non-Viral Gene Delivery Technologies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Viral Gene Delivery Technologies Market

34. Recent Developments In The Non-Viral Gene Delivery Technologies Market

35. Non-Viral Gene Delivery Technologies Market High Potential Countries, Segments and Strategies

  • 35.1 Non-Viral Gene Delivery Technologies Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Non-Viral Gene Delivery Technologies Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Non-Viral Gene Delivery Technologies Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer